Anson Funds Management LP - Oct 20, 2023 Form 4 Insider Report for MEI Pharma, Inc. (MEIP)

Role: 10%+ Owner
Signature: /s/ Bruce R. Winson, manager of Anson Management GP LLC, general partner of Anson Funds Management LP
Stock symbol: MEIP
Transactions as of: Oct 20, 2023
Transactions value $: $1,253,000
Form type: 4
Date filed: 10/24/2023, 07:32 PM
Previous filing: Oct 13, 2023
Next filing: Feb 26, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MEIP	Common Stock	Exercise of in-the-money or at-the-money derivative security	$1M	+143K	+15.66%	$7.00	1.06M	Oct 20, 2023	See footnotes	F1, F2, F3
transaction	MEIP	Common Stock	Exercise of in-the-money or at-the-money derivative security	$251K	+35.8K	+3.39%	$7.00	1.09M	Oct 20, 2023	See footnotes	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MEIP	Put Option (obligation to buy)	Exercise of in-the-money or at-the-money derivative security	$0	-1.43K	-16.85%	$0.00	7.07K	Oct 20, 2023	Common Stock	143K	$7.00	See footnotes	F1, F2, F3
transaction	MEIP	Put Option (obligation to buy)	Exercise of in-the-money or at-the-money derivative security	$0	-358	-5.07%	$0.00	6.71K	Oct 20, 2023	Common Stock	35.8K	$7.00	See footnotes	F1, F2, F3
transaction	MEIP	Put Option (obligation to buy)	Expiration of short derivative position	$0	-6.71K	-100%	$0.00^*	0	Oct 20, 2023	Common Stock	671K	$7.00	See footnotes	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the securities of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.
F2	Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
F3	Anson and Anson Advisors hold indirectly the securities of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the securities held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the securities held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.